Ptc Therapeutics (PTCT) Non Operating Income (2012 - 2026)
Ptc Therapeutics (PTCT) posted quarterly Non Operating Income of -$48.5 million for Q2 2026, down 59.7% year-over-year from -$120.3 million in Q2 2025, and up 1.12% quarter-over-quarter from -$49.0 million in Q1 2026.
Ptc Therapeutics (PTCT) Non Operating Income (2012 - 2026) Analysis & Trends
Ptc Therapeutics' Non Operating Income history runs 15 years deep, the most recent figure standing at -$48.5 million for Q2 2026.
- In Q2 2026, Non Operating Income fell 59.7% year-over-year to -$48.5 million; the TTM figure through Jun 2026 stood at -$185.3 million (down 25.95% YoY), while the FY2025 annual figure was -$152.2 million, up 8.84% from the prior year.
- Non Operating Income for Q2 2026 stood at -$48.5 million, up from -$49.0 million in the prior quarter.
- The five-year high for Non Operating Income was -$20.9 million in Q3 2022, with the low at -$55.2 million in Q4 2025.
- The 5-year median for Non Operating Income is -$33.3 million (2025), against an average of -$35.4 million.
- The sharpest annual moves came in 2023 and 2025: Non Operating Income plunged 80.71% in 2023, then soared 30.2% in 2025.
- Ptc Therapeutics' Non Operating Income stood at -$24.5 million in 2022, then slumped by 80.71% to -$44.3 million in 2023, then gained by 7.26% to -$41.1 million in 2024, then plunged by 34.41% to -$55.2 million in 2025, then advanced by 12.15% to -$48.5 million in 2026.
- Business Quant data shows PTCT's Non Operating Income at -$48.5 million in Q2 2026, -$49.0 million in Q1 2026, and -$55.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Ptc Therapeutics | 5.97 Bn | 3.75 Bn | 340.60 Mn | -48.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -48.48 Mn |
| Mar 31, 2026 | -49.03 Mn |
| Dec 31, 2025 | -55.19 Mn |
| Sep 30, 2025 | -32.59 Mn |
| Jun 30, 2025 | -30.36 Mn |
| Mar 31, 2025 | -34.09 Mn |
| Dec 31, 2024 | -41.06 Mn |
| Sep 30, 2024 | -41.61 Mn |
| Jun 30, 2024 | -43.49 Mn |
| Mar 31, 2024 | -40.83 Mn |
| Dec 31, 2023 | -44.28 Mn |
| Sep 30, 2023 | -28.16 Mn |
| Jun 30, 2023 | -29.42 Mn |
| Mar 31, 2023 | -27.33 Mn |
| Dec 31, 2022 | -24.50 Mn |
| Sep 30, 2022 | -20.88 Mn |
| Jun 30, 2022 | -21.98 Mn |
| Mar 31, 2022 | -23.51 Mn |
| Dec 31, 2021 | -22.50 Mn |
| Sep 30, 2021 | -21.80 Mn |